Discrepancies in the P-glycoprotein-mediated transport of 18F-MPPF: A pharmacokinetic study in mice and non-human primates

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2468-2476

  Tournier, Nicolas ^a   Cisternino, Salvatore ^b   Peyronneau, Marie Anne ^a   Goutal, Sébastien ^a   Dolle, Frédéric ^a   Scherrmann, Jean Michel ^b   Bottlaender, Michel ^a   Saba, Wadad ^a   Valette, Héric ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b INSERM   (France)

Author keywords

18F MPPF; Blood brain barrier; P glycoprotein; Plasma protein binding; Positron emission tomography

Indexed keywords

4 FLUORO N [2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL] N PYRIDIN 2 YL BENZAMIDE; CYCLOSPORIN A; DRUG METABOLITE; FLUORODEOXYGLUCOSE F 18; MULTIDRUG RESISTANCE PROTEIN; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TRANSPORT; DRUG UPTAKE; EXPERIMENTAL MOUSE; IN VITRO STUDY; ISOTOPE LABELING; MALE; METABOLITE; MOUSE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; FLUORINE RADIOISOTOPES; MICE; P-GLYCOPROTEINS; PAPIO; POSITRON-EMISSION TOMOGRAPHY;

EID: 84866730368     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0776-7     Document Type: Article

References (44)

1. Scherrmann J-M. Transporters in absorption, distribution, and elimination. Chem Biodivers. 2009;6(11):1933-42.
2. Pike VW. PET radiotracers: Crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30(8):431-40.
3. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.
4. Tournier N, Decléves X, Saubaméa B, Scherrmann J-M, Cisternino S. Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: Implications for neuropsychopharmacology. Curr Pharm Des. 2011;17(26):2829-42.
5. Bartels AL. Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr Pharm Des. 2011;17(26):2771-7.
6. Aronica E, Sisodiya SM, Gorter JA. Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev. 2011 [Epub ahead of print].
7. van Assema DME, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, et al. Blood-brain barrier Pglycoprotein function in Alzheimer's disease. Brain. 2011; [Epub ahead of print].
8. Hall MD, Pike VW. Avoiding barriers to PET radioligand development: Cellular assays of brain efflux transporters. J Nucl Med. 2011;52(3):338-40.
9. Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
10. Wooten DW, Moraino JD, Hillmer AT, Engle JW, Dejesus OJ, Murali D, et al. In vivo kinetics of [F-18]MEFWAY: A comparison with [C-11]WAY100635 and [F-18]MPPF in the nonhuman primate. Synapse. 2011;65(7):592-600.
11. Lacan G, Plenevaux A, Rubins DJ, Way BM, Defraiteur C, Lemaire C, et al. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: MicroPET and ex vivo studies. Eur J Nucl Med Mol Imaging. 2008;35(12):2256-66.
12. Passchier J, van Waarde A, Doze P, Elsinga PH, Vaalburg W. Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats. Eur J Pharmacol. 2000;407(3):273-80.
13. la Fougére C, Böning G, Bartmann H, Wängler B, Nowak S, Just T, et al. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage. 2010;49(2):1406-15.
14. Bartmann H, Fuest C, la Fougere C, Xiong G, Just T, Schlichtiger J, et al. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: Proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia. 2010;51(9):1780-90.
15. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med. 2007;48(1):81-7.
16. Elsinga PH, Hendrikse NH, Bart J, van Waarde A, Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol. 2005;7(1):37-44.
17. Hammers A, Bouvard S, Costes N, PereiradeSouza N, Keihaninejad S, Le Bars D, et al. Impact of P-glycoprotein on the distribution of [18F]-MPPF in pharmacoresistant temporal lobe epilepsia [abstract]. Epilepsia. 2010;51(Suppl):48.
18. Tournier N, Valette H, Peyronneau M-A, Saba W, Goutal S, Kuhnast B, et al. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): An in vitro screening. J Nucl Med. 2011;52(3):415-23.
19. Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, et al. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res. 2006;23(7):1460-72.
20. Zolnerciks JK, Booth-Genthe CL, Gupta A, Harris J, Unadkat JD. Substrate-and species-dependent inhibition of p-glycoproteinmediated transport: Implications for predicting in vivo drug interactions. J Pharm Sci. 2011; [Epub ahead of print].
21. Le Bars D, Lemaire C, Ginovart N, Plenevaux A, Aerts J, Brihaye C, et al. High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol. 1998;25(4):343-50.
22. Valette H, Xiao Y, Peyronneau M-A, Damont A, Kozikowski AP, Wei Z-L, et al. 18F-ZW-104: A new radioligand for imaging neuronal nicotinic acetylcholine receptors-in vitro binding properties and PET studies in baboons. J Nucl Med. 2009;50(8):1349-55.
23. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740-7.
24. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008;55(8):1364-75.
25. Cattelotte J, André P, Ouellet M, Bourasset F, Scherrmann J-M, Cisternino S. In situ mouse carotid perfusion model: Glucose and cholesterol transport in the eye and brain. J Cereb Blood Flow Metab. 2008;28(8):1449-59.
26. Aznavour N, Zimmer L. [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology. 2007;52(3):695-707.
27. Eyal S, Chung FS, Muzi M, Link JM, Mankoff DA, Kaddoumi A, et al. Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate. J Nucl Med. 2009;50(5):798-806.
28. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J PharmSci. 1998;87(11):1322-30.
29. Ma Y, Lang L, Kiesewetter DO, Eckelman WC. Liquid chromatography-tandem mass spectrometry identification of metabolites of three phenylcarboxyl derivatives of the 5-HT(1A) antagonist, N-(2-(4-(2-methoxyphenyl)-1-piperazinyl) ethyl)-N-(2-pyridyl) trans-4-fluorocyclohexanecarboxamide (FCWAY), produced by human and rat hepatocytes. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;780(1):99-110.
30. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003;10(2):159-65.
31. Carson RE, Wu Y, Lang L, Ma Y, Der MG, Herscovitch P, et al. Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs. J Cereb Blood Flow Metab. 2003;23(2):249-60.
32. Plenevaux A, Weissmann D, Aerts J, Lemaire C, Brihaye C, Degueldre C, et al. Tissue distribution, autoradiography, and metabolism of 4-(2'-methoxyphenyl) -1-[2' -[N-2?-pyridinyl)-p-[(18)F] fluorobenzamido]ethyl]piperazine (p-[(18)F]MPPF), a new serotonin 5-HT(1A) antagonist for positron emission tomography: An in vivo study in rats. J Neurochem. 2000;75(2):803-11.
33. Lang L, Jagoda E, Schmall B, Vuong BK, Adams HR, Nelson DL, et al. Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem. 1999;42(9):1576-86.
34. Costes N, Merlet I, Zimmer L, Lavenne F, Cinotti L, Delforge J, et al. Modeling [18-F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection. J Cereb Blood Flow Metab. 2002;22(6):753-65.
35. Passchier J, van Waarde A, Vaalburg W, Willemsen AT. On the quantification of [18F]MPPF binding to 5-HT1A receptors in the human brain. J Nucl Med. 2001;42(7):1025-31.
36. Tournier N, Chevillard L,Megarbane B, Pirnay S, Scherrmann J-M, Decléves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010;13(7):905-15.
37. Zhang C, Zuo Z, Kwan P, Baum L. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011;52 (10):1894-904.
38. Mandula H, Parepally JM, Feng R, Smith QR. Role of site-specific binding to plasma albumin in drug availability to brain. J Pharmacol Exp Ther. 2006;317(2):667-75.
39. Passchier J, van Waarde A, Pieterman RM, Elsinga PH, Pruim J, Hendrikse HN, et al. In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF. J Nucl Med. 2000;41(11):1830-5.
40. Toffoli G, Aita P, Sorio R, Corona G, Bertola A, Colussi AM, et al. Effect of cyclosporin A on protein binding of teniposide in cancer patients. Anticancer Drugs. 1999;10(6):511-8.
41. Liow JS, Lu S, McCarron JA, Hong J, Musachio JL, Pike VW, et al. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse. 2007;61(2):96-105.
42. Yasuno F, Zoghbi SS, McCarron JA, Hong J, Ichise M, Brown AK, et al. Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. Synapse. 2006;60(7):510-20.
43. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Langström B, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37(3):635-43.
44. Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, et al. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med. 2008;49(4):649-56.